Zemplar

ApprovedSmall molecule

Sanofi

Zemplar is one of 94 small molecule programs targeting Diabetic Nephropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Secondary HyperparathyroidismActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Diabetic NephropathyPhase 2

Active, not recruiting

Secondary HyperparathyroidismApproved

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Zemplar

Sanofi

Approved

7 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Sovaldi

Gilead

Preclinical

1 6

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

PROCRIT

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease7 trials

Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease

Completed·EErling Bjerregaard Pedersen·Phase 2·NCT01136564·30 enrolled

Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease

Completed·—·Phase 2/3·NCT01204528·36 enrolled

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

Unknown status·SScott and White Hospital & Clinic·N/A·NCT01792206·60 enrolled

Show 4 more trials

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Completed·AAbbott·Phase 3·NCT00091975·78 enrolled

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Terminated·AAbbott·Phase 4·NCT00062699·2,200 enrolled

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

Completed·AAbbott·Phase 4·NCT00257920·41 enrolled

Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis

Completed·AAbbott·Phase 4·NCT00091481·201 enrolled

Absorption1 trial

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Completed·AAbbott·Phase 4·NCT00073710·30 enrolled

Diabetic Nephropathy1 trial

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Completed·AAbbott·Phase 2·NCT00421733·281 enrolled

Hemodialysis1 trial

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Completed· Sanofi logo

Sanofi·Phase 4·NCT00454350·12 enrolled

Secondary Hyperparathyroidism1 trial

Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

Completed·AAbbott·Phase 4·NCT00891813·100 enrolled

1 more indication

Unspecified1 trial

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Completed· Sanofi logo

Sanofi·Phase 4·NCT00463021·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Zemplar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zemplar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zemplar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Zemplar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease7 trials

Absorption1 trial

Diabetic Nephropathy1 trial

Hemodialysis1 trial

Secondary Hyperparathyroidism1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News